Incidence and risk factors for carbapenem-and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 2, 2014, Pages 81-88

  Kim, Sun Bean ^a   Min, Yoo Hong ^a   Cheong, June Won ^a   Kim, Jin Seok ^a   Kim, Soo Jeong ^a   Ku, Nam Su ^a   Jeong, Su Jin ^a   Han, Sang Hoon ^a   Choi, Jun Yong ^a   Song, Young Goo ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acinetobacter baumannii; Bacteremia; Hematopoietic stem cell transplantation; Multidrug resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEALTHCARE ASSOCIATED INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA; RISK ASSESSMENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; BACTEREMIA; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS;

EID: 84892641728     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.857042     Document Type: Article

References (34)

1. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13: 196-8.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82.
3. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63.
4. Playford EG, Craig JC, Iredell J R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65: 204-11.
5. Oliveira AL, de Souza M, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007; 39: 775-81.
6. Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res 2009; 42: 289-93.
7. Chan PC, Huang LM, Lin HC, Chang LY, Chen ML, Lu CY, et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2007; 28: 423-9.
8. Zhong L, Men TY, Li H, Peng ZH, Gu Y, Ding X, et al. Multidrug-resistant Gram-negative bacterial infections after liver transplantation-spectrum and risk factors. J Infect 2012; 64: 299-310.
9. Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant 2010; 15: 676-682.
10. Candel FJ, Calvo N, Head J, Sanchez A, Matesanz M, Culebras E, et al. Acombination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter 2010; 23: 103-8.
11. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broadspectrum cephalosporin resistance on outcome. Clin Infect Dis 2004; 39: 812-8.
12. Michalopoulos A, Falagas ME, Karatza DC, Alexandropoulou P, Papadakis E, Gregorakos L, et al. Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant Gram-negative primary bacteremia of critically ill patients. Am J Infect Control 2011; 39: 396-400.
13. Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011; 52: 879-91.
14. Malone L, Kwon D H. Carbapenem-associated multidrugresistant Acinetobacter baumanniiare sensitised by aztreonam in combination with polyamines. Int J Antimicrob Agents 2013; 41: 70-74.
15. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of defi nitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 1619-29.
16. Paterson DL, Doi Y. Astep closer to extreme drug resistance (XDR) in Gram-negative bacilli. Clin Infect Dis 2007; 45: 1179-81.
17. Peffault de Latour R, Calado RT, Busson M, Abrams J, Adoui N, Robin M, et al. Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood 2012; 120: 3353-9.
18. Jimenez-Zepeda VH, Trudel S, Reece DE, Chen C, Rabea AM, Kukreti V. Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation. Am J Hematol 2011; 86: 873-5.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8.
20. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-64.
21. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis 2007; 20: 408-11.
22. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernandez-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009; 30: 257-63.
23. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multidrug resistance. Eur J Clin Microbiol Infect Dis 2008; 27: 607-12.
24. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Southeast Asian J Trop Med Public Health 2011; 42: 693-703.
25. Kim SE, Park BH, Son JY, Kim EY, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 2010; 10: 228.
26. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenemresistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci 2012; 27: 471-5.
27. Lee NY, Chang TC, Wu CJ, Chang CM, Lee HC, Chen PL, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010; 61: 219-27.
28. Shih MJ, Lee NY, Lee HC, Chang CM, Wu CJ, Chen PL, et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect 2008; 41: 118-23.
29. Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung 2010; 188: 381-5.
30. Kim YJ, Yoon JH, Kim SI, Hong KW, Kim JI, Choi JY, et al. High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 2011; 43: 2397-9.
31. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
32. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-93.
33. Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012; 55: 209-15.
34. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44: 87-93.